Colvin B T, Ainsworth M, Machin S J, Mackie I J, Smith J K, Winkelman L, Haddon M E
Clin Lab Haematol. 1986;8(2):85-92. doi: 10.1111/j.1365-2257.1986.tb00082.x.
Three patients who have been given intermediate purity NHS heat-treated factor VIII concentrate have been followed prospectively for 7-10 months. None had previously received more than six donor units of blood products containing factor VIII. There were no clinical side effects from concentrate administration, haemostasis was satisfactory and no patient developed clinical or laboratory evidence of hepatitis or HTLV III/LAV infection. Heat treatment resulted in the loss of slightly more than 20% of factor VIII activity but in vivo recovery of factor VIII and half disappearance times were within the expected range.
三名接受中等纯度NHS热处理的凝血因子VIII浓缩物的患者被前瞻性随访了7至10个月。此前，他们接受的含有凝血因子VIII的血液制品均不超过六个供体单位。输注浓缩物后未出现临床副作用，止血效果令人满意，且没有患者出现肝炎或HTLV III/LAV感染的临床或实验室证据。热处理导致凝血因子VIII活性损失略超过20%，但凝血因子VIII的体内回收率和半衰期在预期范围内。
